Tag: report

Czech Republic's construction industry is set for real-term growth of 3.3% in 2025 after a 0.7% contraction in 2024, driven by hospitality and transport infrastructure investments. Supporting this, Czech government plans and EU Recovery funds will boost the sector, with annual growth projected at 3.4% till 2029.

Continued GMV growth
Increased Gross margin approximately 210 basis points
Reduced inventory for the eighth consecutive quarter

PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) will be conducted virtually on Thursday, June 12, 2025, at 9:30 AM ET, as previously disclosed in its Proxy Statement that was filed with the Securities and Exchange Commission (“SEC”) on April 24, 2025.

Unlock growth opportunities in Tanzania's construction sector with insights on market trends and forecasts from 2025-2029. Explore investment impacts, key projects, and industry dynamics across commercial, infrastructure, and energy sectors. Discover strategic insights into Tanzania's pipeline projects and developments.

New leadership focuses on business simplification and brand enablers

The Micro Thermoelectric Modules market offers significant opportunities in energy-efficient applications across consumer electronics, automotive, aerospace, and healthcare. Key drivers include a push for sustainable power solutions and advancements in thermoelectric materials and manufacturing, despite challenges in production costs.

HYDERABAD, INDIA & REYKJAVIK, ICELAND (June 5, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy’s and Alvotech’s proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate.